Athersys, Inc. (NASDAQ:ATHX) EVP John J. Harrington sold 7,500 shares of Athersys stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $1.68, for a total value of $12,600.00. Following the completion of the transaction, the executive vice president now directly owns 658,474 shares of the company’s stock, valued at $1,106,236.32. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Athersys, Inc. (ATHX) traded up $0.07 on Tuesday, hitting $1.86. The stock had a trading volume of 851,601 shares, compared to its average volume of 1,016,421. Athersys, Inc. has a 12 month low of $1.02 and a 12 month high of $2.63.

Several research analysts have recently weighed in on the company. ValuEngine lowered Athersys from a “hold” rating to a “sell” rating in a research report on Tuesday, December 5th. Maxim Group set a $12.00 price objective on Athersys and gave the stock a “buy” rating in a research report on Thursday, November 16th. Finally, Zacks Investment Research lowered Athersys from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Athersys has an average rating of “Hold” and an average price target of $7.17.

Institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE grew its stake in shares of Athersys by 17.2% in the 1st quarter. Bank of America Corp DE now owns 61,580 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 9,019 shares during the period. Thompson Davis & CO. Inc. grew its stake in shares of Athersys by 743.9% in the 3rd quarter. Thompson Davis & CO. Inc. now owns 64,303 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 56,683 shares during the period. SG Americas Securities LLC grew its stake in shares of Athersys by 329.7% in the 2nd quarter. SG Americas Securities LLC now owns 73,434 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 56,345 shares during the period. State of Wisconsin Investment Board acquired a new stake in shares of Athersys in the 2nd quarter valued at about $113,000. Finally, Blair William & Co. IL grew its stake in shares of Athersys by 708.0% in the 2nd quarter. Blair William & Co. IL now owns 80,804 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 70,804 shares during the period. Institutional investors own 21.01% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Athersys, Inc. (ATHX) EVP John J. Harrington Sells 7,500 Shares” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/12/19/athersys-inc-athx-evp-john-j-harrington-sells-7500-shares.html.

Athersys Company Profile

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Insider Buying and Selling by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.